Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Polymorphisms in NFkB, PXR, LXR and risk of colorectal cancer in a prospective study of Danes

Authors: Vibeke Andersen, Jane Christensen, Kim Overvad, Anne Tjønneland, Ulla Vogel

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

Transcription factors and nuclear receptors constitute a link between exposure to heterocyclic amines and polycyclic aromatic hydrocarbons from meat and tobacco smoke and colorectal cancer (CRC) risk. The aim of this study was to investigate if polymorphisms in nuclear factor kappa-B, pregnane X receptor, and liver X receptor were associated with risk of CRC, and to investigate possible interactions with lifestyle factors such as smoking, meat consumption, and NSAID use.

Methods

The polymorphisms nuclear factor kappa-B (NFkB, NFKB1) -94 insertion/deletion ATTG (rs28362491), pregnane X receptor (PXR, NR1I2) A-24381C (rs1523127), C8055T (rs2276707), A7635G (rs6785049), liver X receptor (LXR-β, NR1H3) C-rs1405655T, T-rs2695121C were assessed together with lifestyle factors in a nested case-cohort study of 378 CRC cases and 756 random participants from the Danish prospective Diet, Cancer and Health study of 57,053 persons.

Results

Carriers of NFkB -94deletion were at 1.45-fold higher risk of CRC than homozygous carriers of the insertion allele (incidence rate ratio (IRR) = 1.45, 95% confidence interval (95% CI): 1.10-1.92). There was interaction between this polymorphism and intake of red and processed meat in relation to CRC risk. Carriers of NFkB -94deletion were at 3% increased risk pr 25 gram meat per day (95% CI: 0.98-1.09) whereas homozygous carriers of the insertion were not at increased risk (p for interaction = 0.03). PXR and LXR polymorphisms were not associated with CRC risk. There was no interaction between use of nonsteroid antiinflammatory drugs (NSAID) or smoking status and NFkB, PXR or LXR polymorphisms.

Conclusions

A polymorphism in NFkB was associated with CRC risk and there was interaction between this polymorphism and meat intake in relation to CRC risk. This study suggests a role for NFkB in CRC aetiology.
Appendix
Available only for authorised users
Literature
1.
Huxley RR, nsary-Moghaddam A, Clifton P, Czernichow S, Parr CL, Woodward M: The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence. Int J Cancer. 2009, 125: 171-180. 10.1002/ijc.24343.CrossRefPubMed
2.
Aggarwal BB, Vijayalekshmi RV, Sung B: Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res. 2009, 15: 425-430. 10.1158/1078-0432.CCR-08-0149.CrossRefPubMed
3.
4.
5.
Santarelli RL, Pierre F, Corpet DE: Processed meat and colorectal cancer: a review of epidemiologic and experimental evidence. Nutr Cancer. 2008, 60: 131-144. 10.1080/01635580701684872.CrossRefPubMedPubMedCentral
6.
Oates PS, West AR: Heme in intestinal epithelial cell turnover, differentiation, detoxification, inflammation, carcinogenesis, absorption and motility. World J Gastroenterol. 2006, 12: 4281-4295.CrossRefPubMedPubMedCentral
7.
Liang PS, Chen TY, Giovannucci E: Cigarette smoking and colorectal cancer incidence and mortality: systematic review and meta-analysis. Int J Cancer. 2009, 124: 2406-2415. 10.1002/ijc.24191.CrossRefPubMed
8.
Tsoi KK, Pau CY, Wu WK, Chan FK, Griffiths S, Sung JJ: Cigarette smoking and the risk of colorectal cancer: a meta-analysis of prospective cohort studies. Clin Gastroenterol Hepatol. 2009, 7: 682-688. 10.1016/j.cgh.2009.02.016.CrossRefPubMed
9.
10.
11.
Seitz M, Wirthmuller U, Moller B, Villiger PM: The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford). 2007, 46: 93-96. 10.1093/rheumatology/kel175.CrossRef
12.
Flossmann E, Rothwell PM: Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007, 369: 1603-1613. 10.1016/S0140-6736(07)60747-8.CrossRefPubMed
13.
Friis S, Poulsen AH, Sorensen HT, Tjonneland A, Overvad K, Vogel U, et al: Aspirin and other non-steroidal anti-inflammatory drugs and risk of colorectal cancer: A Danish cohort study. Cancer Causes Control. 2009
14.
Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G: Aspirin, salicylates, and cancer. Lancet. 2009, 373: 1301-1309. 10.1016/S0140-6736(09)60243-9.CrossRefPubMed
15.
Stark LA, Din FV, Zwacka RM, Dunlop MG: Aspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J. 2001, 15: 1273-1275.PubMed
16.
Goel A, Boland CR: Recent insights into the pathogenesis of colorectal cancer. Curr Opin Gastroenterol. 2009
17.
Vogel U, Christensen J, Dybdahl M, Friis S, Hansen RD, Wallin H, et al: Prospective study of interaction between alcohol, NSAID use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer. Mutat Res. 2007, 624: 88-100.CrossRefPubMed
18.
Andersen V, Agerstjerne L, Jensen D, Ostergaard M, Saebo M, Hamfjord J, et al: The multidrug resistance 1 (MDR1) gene polymorphism G-rs3789243-A is not associated with disease susceptibility in Norwegian patients with colorectal adenoma and colorectal cancer; a case control study. BMC Med Genet. 2009, 10: 18-10.1186/1471-2350-10-18.CrossRefPubMedPubMedCentral
19.
Hansen RD, Sorensen M, Tjonneland A, Overvad K, Wallin H, Raaschou-Nielsen O, et al: XPA A23G, XPC Lys939Gln, XPD Lys751Gln and XPD Asp312Asn polymorphisms, interactions with smoking, alcohol and dietary factors, and risk of colorectal cancer. Mutat Res. 2007, 619: 68-80.CrossRefPubMed
20.
Andersen V, Ostergaard M, Christensen J, Overvad K, Tjonneland A, Vogel U: Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) gene and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer. 2009, 9: 407-10.1186/1471-2407-9-407.CrossRefPubMedPubMedCentral
21.
Scotto KW: Transcriptional regulation of ABC drug transporters. Oncogene. 2003, 22: 7496-7511. 10.1038/sj.onc.1206950.CrossRefPubMed
22.
Urquhart BL, Ware JA, Tirona RG, Ho RH, Leake BF, Schwarz UI, et al: Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. Pharmacogenet Genomics. 2008, 18: 439-448. 10.1097/FPC.0b013e3282f974dc.CrossRefPubMedPubMedCentral
23.
Teng S, Piquette-Miller M: Regulation of transporters by nuclear hormone receptors: implications during inflammation. Mol Pharm. 2008, 5: 67-76. 10.1021/mp700102q.CrossRefPubMed
24.
Chisaki I, Kobayashi M, Itagaki S, Hirano T, Iseki K: Liver X receptor regulates expression of MRP2 but not that of MDR1 and BCRP in the liver. Biochim Biophys Acta. 2009, 1788: 2396-2403. 10.1016/j.bbamem.2009.08.014.CrossRefPubMed
25.
Wang D, DuBois RN: Inflammatory mediators and nuclear receptor signaling in colorectal cancer. Cell Cycle. 2007, 6: 682-685.CrossRefPubMed
26.
Karin M: Nuclear factor-kappaB in cancer development and progression. Nature. 2006, 441: 431-436. 10.1038/nature04870.CrossRefPubMed
27.
Kundu JK, Surh YJ: Inflammation: gearing the journey to cancer. Mutat Res. 2008, 659: 15-30. 10.1016/j.mrrev.2008.03.002.CrossRefPubMed
28.
Sebban H, Courtois G: NF-kappaB and inflammation in genetic disease. Biochem Pharmacol. 2006, 72: 1153-1160. 10.1016/j.bcp.2006.08.006.CrossRefPubMed
29.
De Vry CG, Prasad S, Komuves L, Lorenzana C, Parham C, Le T, et al: Non-viral delivery of nuclear factor-kappaB decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis. Gut. 2007, 56: 524-533. 10.1136/gut.2006.096487.CrossRefPubMed
30.
Greten FR, Arkan MC, Bollrath J, Hsu LC, Goode J, Miething C, et al: NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell. 2007, 130: 918-931. 10.1016/j.cell.2007.07.009.CrossRefPubMedPubMedCentral
31.
Karban AS, Okazaki T, Panhuysen CI, Gallegos T, Potter JJ, Bailey-Wilson JE, et al: Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet. 2004, 13: 35-45. 10.1093/hmg/ddh008.CrossRefPubMed
32.
Lewander A, Butchi AK, Gao J, He LJ, Lindblom A, Arbman G, et al: Polymorphism in the promoter region of the NFKB1 gene increases the risk of sporadic colorectal cancer in Swedish but not in Chinese populations. Scand J Gastroenterol. 2007, 42: 1332-1338. 10.1080/00365520701396026.CrossRefPubMed
33.
di MA, Marinis ED, Ascenzi P, Marino M: Nuclear receptors CAR and PXR: Molecular, functional, and biomedical aspects. Mol Aspects Med. 2009, 30: 297-343. 10.1016/j.mam.2009.04.002.CrossRef
34.
Zhou C, Tabb MM, Nelson EL, Grun F, Verma S, Sadatrafiei A, et al: Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. J Clin Invest. 2006, 116: 2280-2289. 10.1172/JCI26283.CrossRefPubMedPubMedCentral
35.
Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A, et al: The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics. 2001, 11: 555-572. 10.1097/00008571-200110000-00003.CrossRefPubMed
36.
Rizzo G, Fiorucci S: PPARs and other nuclear receptors in inflammation. Curr Opin Pharmacol. 2006, 6: 421-427. 10.1016/j.coph.2006.03.012.CrossRefPubMed
37.
Infante J, Rodriguez-Rodriguez E, Mateo I, Llorca J, Vazquez-Higuera JL, Berciano J, et al: Gene-gene interaction between heme oxygenase-1 and liver X receptor-beta and Alzheimer's disease risk. Neurobiol Aging. 2008
38.
Tjonneland A, Olsen A, Boll K, Stripp C, Christensen J, Engholm G, et al: Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: a population-based prospective cohort study of 57,053 men and women in Denmark. Scand J Public Health. 2007, 35: 432-441. 10.1080/14034940601047986.CrossRefPubMed
39.
Hansen R, Saebo M, Skjelbred CF, Nexo BA, Hagen PC, Bock G, et al: GPX Pro198Leu and OGG1 Ser326Cys polymorphisms and risk of development of colorectal adenomas and colorectal cancer. Cancer Lett. 2005, 229: 85-91. 10.1016/j.canlet.2005.04.019.CrossRefPubMed
40.
Hansen RD, Sorensen M, Tjonneland A, Overvad K, Wallin H, Raaschou-Nielsen O, et al: A haplotype of polymorphisms in ASE-1, RAI and ERCC1 and the effects of tobacco smoking and alcohol consumption on risk of colorectal cancer: a Danish prospective case-cohort study. BMC Cancer. 2008, 8: 54-10.1186/1471-2407-8-54.CrossRefPubMedPubMedCentral
41.
42.
Prosky L, Asp NG, Furda I, DeVries JW, Schweizer TF, Harland BF: Determination of total dietary fiber in foods and food products: collaborative study. J Assoc Off Anal Chem. 1985, 68: 677-679.PubMed
43.
Tjonneland A, Overvad K, Haraldsdottir J, Bang S, Ewertz M, Jensen OM: Validation of a semiquantitative food frequency questionnaire developed in Denmark. Int J Epidemiol. 1991, 20: 906-912. 10.1093/ije/20.4.906.CrossRefPubMed
44.
Tjonneland A, Haraldsdottir J, Overvad K, Stripp C, Ewertz M, Jensen OM: Influence of individually estimated portion size data on the validity of a semiquantitative food frequency questionnaire. Int J Epidemiol. 1992, 21: 770-777. 10.1093/ije/21.4.770.CrossRefPubMed
45.
Friis S, Poulsen AH, Sorensen HT, Tjonneland A, Overvad K, Vogel U, et al: Aspirin and other non-steroidal anti-inflammatory drugs and risk of colorectal cancer: a Danish cohort study. Cancer Causes Control. 2009, 20: 731-740. 10.1007/s10552-008-9286-7.CrossRefPubMed
46.
Vogel U, Christensen J, Dybdahl M, Friis S, Hansen RD, Wallin H, et al: Prospective study of interaction between alcohol, NSAID use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer. Mutat Res. 2007, 624: 88-100.CrossRefPubMed
47.
Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988, 16: 1215-10.1093/nar/16.3.1215.CrossRefPubMedPubMedCentral
48.
Vangsted AJ, Klausen TW, Ruminski W, Gimsing P, Andersen NF, Gang AO, et al: The polymorphism IL-1beta T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT. Bone Marrow Transplant. 2009, 43: 539-545. 10.1038/bmt.2008.351.CrossRefPubMed
49.
Barlow WE, Ichikawa L, Rosner D, Izumi S: Analysis of case-cohort designs. J Clin Epidemiol. 1999, 52: 1165-1172. 10.1016/S0895-4356(99)00102-X.CrossRefPubMed
50.
Barlow WE: Robust variance estimation for the case-cohort design. Biometrics. 1994, 50: 1064-1072. 10.2307/2533444.CrossRefPubMed
51.
Hansen RD, Sorensen M, Tjonneland A, Overvad K, Wallin H, Raaschou-Nielsen O, et al: A haplotype of polymorphisms in ASE-1, RAI and ERCC1 and the effects of tobacco smoking and alcohol consumption on risk of colorectal cancer: a Danish prospective case-cohort study. BMC Cancer. 2008, 8: 54-10.1186/1471-2407-8-54.CrossRefPubMedPubMedCentral
52.
Raaschou-Nielsen O, Sorensen M, Overvad K, Tjonneland A, Vogel U: Polymorphisms in nucleotide excision repair genes, smoking and intake of fruit and vegetables in relation to lung cancer. Lung Cancer. 2007
53.
Raaschou-Nielsen O, Sorensen M, Hansen RD, Frederiksen K, Tjonneland A, Overvad K, et al: GPX1 Pro198Leu polymorphism, interactions with smoking and alcohol consumption, and risk for lung cancer. Cancer Lett. 2007, 247: 293-300. 10.1016/j.canlet.2006.05.006.CrossRefPubMed
54.
Vogel U, Christensen J, Wallin H, Friis S, Nexo BA, Raaschou-Nielsen O, et al: Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study. Mutat Res. 2008, 639: 89-100.CrossRefPubMed
55.
Sorensen M, Raaschou-Nielsen O, Hansen RD, Tjonneland A, Overvad K, Vogel U: Interactions between the OGG1 Ser326Cys polymorphism and intake of fruit and vegetables in relation to lung cancer. Free Radic Res. 2006, 40: 885-891. 10.1080/10715760600733129.CrossRefPubMed
56.
Vogel U, Segel S, Dethlefsen C, Tjonneland A, Saber AT, Wallin H, et al: Associations between COX-2 polymorphisms, blood cholesterol and risk of acute coronary syndrome. Atherosclerosis. 2010, 209: 155-162. 10.1016/j.atherosclerosis.2009.08.036.CrossRefPubMed
57.
Vogel U, Segel S, Dethlefsen C, Tjonneland A, Saber AT, Wallin H, et al: PPARgamma Pro12Ala polymorphism and risk of acute coronary syndrome in a prospective study of Danes. BMC Med Genet. 2009, 10: 52-10.1186/1471-2350-10-52.CrossRefPubMedPubMedCentral
58.
Jensen MK, Rimm EB, Mukamal KJ, Edmondson AC, Rader DJ, Vogel U, et al: The T111I variant in the endothelial lipase gene and risk of coronary heart disease in three independent populations. Eur Heart J. 2009, 30: 1584-1589. 10.1093/eurheartj/ehp145.CrossRefPubMedPubMedCentral
59.
Jensen MK, Rimm EB, Rader D, Schmidt EB, Sorensen TI, Vogel U, et al: S447X variant of the lipoprotein lipase gene, lipids, and risk of coronary heart disease in 3 prospective cohort studies. Am Heart J. 2009, 157: 384-390. 10.1016/j.ahj.2008.10.008.CrossRefPubMedPubMedCentral
60.
Legrand-Poels S, Zecchinon L, Piret B, Schoonbroodt S, Piette J: Involvement of different transduction pathways in NF-kappa B activation by several inducers. Free Radic Res. 1997, 27: 301-309. 10.3109/10715769709065768.CrossRefPubMed
61.
Dring MM, Goulding CA, Trimble VI, Keegan D, Ryan AW, Brophy KM, et al: The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology. 2006, 130: 341-348. 10.1053/j.gastro.2005.12.008.CrossRefPubMed
62.
Aitken AE, Richardson TA, Morgan ET: Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol. 2006, 46: 123-149. 10.1146/annurev.pharmtox.46.120604.141059.CrossRefPubMed
63.
Wang K, Wan YJ: Nuclear receptors and inflammatory diseases. Exp Biol Med (Maywood). 2008, 233: 496-506. 10.3181/0708-MR-231.CrossRef
64.
Din FV, Dunlop MG, Stark LA: Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis. Br J Cancer. 2004, 91: 381-388.PubMedPubMedCentral
Metadata
Title
Polymorphisms in NFkB, PXR, LXR and risk of colorectal cancer in a prospective study of Danes
Authors
Vibeke Andersen
Jane Christensen
Kim Overvad
Anne Tjønneland
Ulla Vogel
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-484

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue

Research article

Meta-analysis of archived DNA microarrays identifies genes regulated by hypoxia and involved in a metastatic phenotype in cancer cells

Debate

Exclusive and adjuvant radiotherapy in breast cancer patients with synchronous metastases

Research article

Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model

Research article

Selective regain of egfr gene copies in CD44+/CD24-/lowbreast cancer cellular model MDA-MB-468

Research article

Methylenetetrahydrofolate reductase C677T polymorphism in patients with gastric and colorectal cancer in a Korean population

Research article

Mutations in the WTX- gene are found in some high-grade microsatellite instable (MSI-H) colorectal cancers
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits